Supernus Pharmaceuticals (SUPN) Non-Current Deffered Revenue (2011 - 2017)

Supernus Pharmaceuticals (SUPN) has 7 years of Non-Current Deffered Revenue data on file, last reported at $1.1 million in Q4 2017.

• Non-Current Deffered Revenue for Q4 2017 came in at $1.1 million, down 23.45% year-over-year; the trailing twelve-month figure through Dec 2017 was $1.1 million (down 23.45% YoY), and the FY2017 annual result was $1.1 million, down 23.45% from the prior year.
• Non-Current Deffered Revenue fell to $1.1 million in Q4 2017 per SUPN's latest filing, from $1.2 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $1.7 million in Q1 2016 and troughed at $738000.0 in Q2 2013.
• A 5-year average of $1.3 million and a median of $1.3 million in 2014 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2013 and 2017: Non-Current Deffered Revenue jumped 358.58% in 2013, then retreated 23.45% in 2017.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $1.4 million in 2013, then fell by 10.09% to $1.3 million in 2014, then gained by 9.11% to $1.4 million in 2015, then grew by 7.99% to $1.5 million in 2016, then retreated by 23.45% to $1.1 million in 2017.
• Business Quant data shows SUPN's Non-Current Deffered Revenue at $1.1 million in Q4 2017, $1.2 million in Q3 2017, and $1.3 million in Q2 2017.